EV NICKEL INC. EQS-Adhoc: APONTIS PHARMA AG: CEO Karlheinz Gast resigns from office for personal reasons
Transparency directive : regulatory news
|
EQS-Ad-hoc: APONTIS PHARMA AG / Key word(s): Personnel Publication of inside information pursuant to Article 17 of the Regulation (EU) No. 596/2014 Monheim am Rhein, 10 July 2023. The Chief Executive Officer (CEO) of APONTIS PHARMA AG (“APONTIS PHARMA” or “Company“, Ticker APPH / ISIN DE000A3CMGM5), Karlheinz Gast, has informed the Supervisory Board today that he is resigning from his office for personal reasons with immediate effect and that he is leaving the Executive Board. The Supervisory Board received and accepted Mr. Gast's resignation at its extraordinary meeting today. The service agreement with Mr. Gast will be canceled by mutual agreement. At the same time, the Supervisory Board appointed Bruno Wohlschlegel as a member of the Executive Board and as CEO for a period of 2 years with an effective date 1 September 2023. Until then, Executive Board member Thomas Milz will manage the Company alone. Investor Relations APONTIS PHARMA press contact CROSS ALLIANCE End of Inside Information
10-Jul-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | APONTIS PHARMA AG |
| Alfred-Nobel-Str. 10 | |
| 40789 Monheim | |
| Germany | |
| E-mail: | ir@apontis-pharma.de |
| Internet: | https://apontis-pharma.de/ |
| ISIN: | DE000A3CMGM5 |
| WKN: | A3CMGM |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Scale), Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1676427 |
| End of Announcement | EQS News Service |
|
|
1676427 10-Jul-2023 CET/CEST